4
Changes in Ownership
MoonLake Immunotherapeutics Filed Acc 0001213900-26-042629
Chief Financial Officer sold 87,795 shares at an average $18.95 ($1,663,935)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Bodenstedt Matthias · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-04-09 | Sale : show line 1 in the form 10b5-1 | −85,870 | $18.94 | $1,626,378 | 1,190,435 | D |
| 2026-04-10 | Sale : show line 2 in the form 10b5-1 | −1,925 | $19.51 | $37,557 | 1,188,510 | D |
| Open-market sales · 87,795 sh · avg $18.95 · $1,663,935 | ||||||
Loading xslF345X06/ownership.xml…